Tuesday, October 9, 2018

Drug Formulation Conference 2019




!!!! has been rescheduled from 8-9 2018 Auckland, New Zealand, to 15-16, 2019 . We apologize for this sudden change. E-mail @ drugformulation50@gmail.com for further query.

Wednesday, September 19, 2018

DRUG FORMULATION CONGRESS 2019

About Conference



17th International Conference on Drug Formulation & Drug Delivery is scheduled to be held during April 15-16, 2019 at Hong Kong. This Drug Formulation Congress 2019  includes a wide range of Keynote presentations, plenary talks, Symposia, Workshops, Exhibitions, Poster presentations and Career development programs

Series Ltd Organizes Conference 3000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The Conference Series LLC ltd website will provide you list and details about the conferences organize worldwide.

Why to Attend???

Drug Formulation Congress 2019 Conference is a multidisciplinary program with broad participation with members from around the globe focused on learning about formulations and drug delivery and its advances. This is your best opportunity to reach the largest assemblage of participants from Pharma research community that is from academia, drug delivery entities, medical groups, related associations, societies and also from government agencies, pharmaceutical, biomedical and medical device industries.

Who should attend and Who You’ll Meet

Directors/Senior Directors/Executive Directors and Vice Presidents/Senior Vice Presidents/Executive Vice Presidents and Heads/Leaders/Partners of

  • CROs and CMOs
  • Pharma Research Sites
  • Pharma/Biotech and Medical Device industries
  • Hospitals, Associations
  • Medical Directors, Principal Investigators, Methodologists, and other Pharmaceutical research professionals along with Academicians: University Faculties like Directors, Senior Professors/Assistant Professors/ Associate Professor, Research Scholars, scientists who are related to pharmaceutical research.


Target Audience

  • PhD Scholars
  • Graduates and Post Graduates
  • Professors, Associate Professors, Assistant Professors
  • Bio instruments Professionals
  • Bio-informatics Professionals
  • Directors, CEO’s of Organizations
  • Supply Chain companies
  • Manufacturing Companies
  • Software development companies
  • Research Institutes and members

Conference Highlights


Special Issues


  • All accepted abstracts will be published in respective Supported International Journals.
  • Abstracts will be provided with Digital Object Identifier by CrossRef

Tuesday, August 14, 2018

Track: 15

                     Business Opportunities in Drug Delivery

Drug Formulation Congress 2018 | Business Opportunities in Drug Delivery


The global market for Business Development of Drug Delivery Technology in 2010 was $131.6 billion and is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2016. The U.S  constituted approximately 59% of the total drug delivery market in 2010 and was $78 billion. It is forecast to reach nearly $103 billion in 2016 at a CAGR of 4.7%. Europe contributed about 27% of the total drug delivery market in 2010 and was $36 billion and is expected to grow to $49 billion by 2016 at a CAGR of 5.6% in 2013, Drug Delivery Global market reached $150.3 billion, according to BCC research. This was an increase from $142 billion the previous year. Given its predicted annual growth the market represents a considerable business opportunity, which has been reflected in increasing number of drug delivery specialists. Consistent quality and competitive costs of product improves Production performance and continuity of supply and Product and technology auditing and due diligence with minimizing Regulatory Issues, quality control, and business development Business opportunities in drug delivery.

November 08-09

For  more details: https://drugformulation.pharmaceuticalconferences.com/
 

Friday, August 10, 2018

Track: 14

                    Recent advancements in BA/BE Research




The aim of bioavailability study is to find out the dosage form influence on the biological performance of the drug, sensitivity to detect differences in the rate and extent of absorption. Bioavailability and bioequivalence study design involves Single dose or multi dose standard 2x 2 crossovers, Parallel groups, for more than two formulations. Study design meant for estimating essential pharmacokinetic parameters differs significantly from a bioequivalence study meant for comparing the test formulation. The results of a pilot study can be used as the sole basis to document BA or BE provided the study’s design and execution are suitable and enough subjects have completed the study
  • Novel Drug Delivery Systems- BA/BE approach
  • Generic drugs: Current claims and future directions
  • BA/BE Studies for Immediate-Release Solid Oral Dosage Forms
  • Bioavailability Study for cancer drugs
  • Bioequivalence analysis of highly variable drugs
  • Food-effect bioavailability and fed bioequivalence studies
November 08-09

For  more details: https://drugformulation.pharmaceuticalconferences.com/

Thursday, August 9, 2018

Track: 13

Bioequivalence Studies and Assessment 




 


Bioequivalence studies are done for both Early & late Clinical Trial formulations, Formulations used in clinical trials and stability studies, if different Clinical trial formulations and to-be-marketed drug product when it comes to cost and productivity metrics, it’s often said that what gets measured gets done. Bioequivalence is determined based on the bioavailability of the innovator medicine versus the generic medicine. The outline for bioequivalence study includes the organization of test and reference items on two events to volunteer subjects, with every organization isolated by a washout period. This Study involves parameters on (Cmax) and (AUC), Statistical evaluation.
Assessment of the bioequivalence of generic versions of certain reference drugs is complicated by the presence of endogenous levels of said compounds which cannot be distinguished from externally derived compound levels following drug administration. If unaccounted for, the presence of endogenous compound biases towards equivalence in bioequivalence studies of these drugs. Bioequivalence assessments may be complicated further as disposition of the exogenous analogue can be subject to various endogenous processes resulting in nonlinear pharmacokinetics. To overcome these inherent biases a number of different strategies have been employed.
  • Pharmaceutical Chemistry and Engineering
  • Analytical Techniques in Chemical Engineering
  • Pharmaceutical Analytical Chemistry
  • Bioequivalence Protocols : In vitro-In vivo correlation
  • Dissolution Studies
  • Genetic Phenotyping
  • Response of clinical studies

For  more details: https://drugformulation.pharmaceuticalconferences.com/ 
 

Wednesday, August 8, 2018

Track: 12

                        Pharmaceutical Regulatory Affairs




Regulatory Affairs contributes essentially to the overall success of drug development, both at early pre-marketing stages and at all times post-marketing. The pharmaceutical industry deals with an increasing number of interesting drug candidates, all of which necessitate the involvement of the Regulatory Affairs’ department. Regulatory Affairs professionals can play a key role in guiding drug development strategy in an increasingly global environment. But they also play an important operational role, for example, by considering the best processes to follow and enabling structured interaction with regulatory authorities. Regulatory Affairs is driven by good science and accordingly nothing remains static.
  • Regulatory Affairs for Clinical Trails
  • Management of Quality Standards
  • Regulatory Affairs Profession
  • Regulatory Consulting & Market Analysis
  • Quality Assurance in Regulatory Affairs
  • Healthcare Regulatory Affairs
  • Pharmaceutical Companies & Regulatory Guidelines
November 08-09

For  more details: https://drugformulation.pharmaceuticalconferences.com/  

Tuesday, August 7, 2018

Track: 11

                 Chemical and Pharmaceutical Engineering


Pharmaceutical engineering is a branch of pharmaceutical science and technology that involves development and manufacturing of products, processes, and components in the pharmaceuticals industry (i.e. drugs & biologics). While developing pharmaceutical products involves many interrelated disciplines (e.g. medicinal chemists, analytical chemists, clinicians/pharmacologists, pharmacists, chemical engineers, biomedical engineers, etc.), the specific subfield of "pharmaceutical engineering" has only emerged recently as a divergent engineering discipline. This now brings the problem-solving principles and quantitative training of engineering to complement the other scientific fields already involved in drug development.
  • Pharmaceutical Engineering
  • Chemical Engineering Research
  • Pharmaceutical Research & Development
  • Technical Chemistry
  • Biomedical Engineering
 
Submit  related to above track in link give below:
 https://drugformulation.pharmaceuticalconferences.com/abstract-submission.php